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The majority of patients with neuroblastoma due to MYCN oncogene amplification and con-
sequent N-Myc oncoprotein over-expression die of the disease. Here our analyses of RNA
sequencing data identify the long noncoding RNA lncNB1 as one of the transcripts most over-
expressed in MYCN-amplified, compared with MYCN-non-amplified, human neuroblastoma cells
and also the most over-expressed in neuroblastoma compared with all other cancers. lncNB1
binds to the ribosomal protein RPL35 to enhance E2F1 protein synthesis, leading to DEPDC1B gene
transcription. The GTPase-activating protein DEPDC1B induces ERK protein phosphorylation and
N-Myc protein stabilization. Importantly, lncNB1 knockdown abolishes neuroblastoma cell clo-
nogenic capacity in vitro and leads to neuroblastoma tumor regression in mice, while high levels
of lncNB1 and RPL35 in human neuroblastoma tissues predict poor patient prognosis. This study
therefore identifies lncNB1 and its binding protein RPL35 as key factors for promoting E2F1 protein
synthesis, N-Myc protein stability and N-Myc-driven oncogenesis, and as therapeutic targets.
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Cancer is the most common cause of death from disease inchildren, and neuroblastoma accounts for approximately15% of all childhood cancer-related deaths. Amplification
of the MYCN oncogene and consequent over-expression of the
N-Myc oncoprotein occur in approximately 25% of human neu-
roblastoma tissues and correlate with poor patient prognosis1,2.
N-Myc oncoprotein, like its analog c-Myc oncoprotein, is sta-
bilized when phosphorylated at Serine 62 (S62) by phosphorylated
ERK protein3,4. Myc oncoproteins induce cell proliferation and
tumorigenesis by regulating gene transcription5,6. In the last three
decades, a number of protein-coding genes have been demon-
strated to enhance the tumorigenic effect of N-Myc and c-Myc5,6.
However, apart from lncUSMycN, CASC15 and NBAT-17–9, little
is known about the roles of long noncoding RNAs (lncRNAs) in
N-Myc-driven neuroblastoma.
LncRNAs regulate gene expression through modulating chro-
matin architecture, gene transcription10, precursor messenger RNA
splicing11, mRNA transport, and post-translational modification12.
Importantly, aberrant lncRNA expression leads to cell proliferation,
differentiation block, resistance to apoptosis, chromosome
instability, cancer cell migration and invasion, tumor initiation and
progression13–15.
While microarrays have identified a number of protein-coding
genes considerably differentially expressed between MYCN-
amplified and non-amplified human neuroblastoma cell lines, the
technology does not cover the majority of lncRNAs. We per-
formed RNA sequencing experiments with RNA from MYCN-
amplified and non-amplified human neuroblastoma cell lines.
Bioinformatics analysis showed that a lncRNA, which we named
lncNB1, was one of the most overexpressed transcripts in MYCN-
amplified neuroblastoma cell lines. lncNB1 binds to the ribosomal
protein RPL35, leading to synthesis of E2F1 protein which induces
DEPDC1B gene transcription. The GTPase-activating protein
DEPDC1B promotes ERK protein phosphorylation, N-Myc pro-
tein phosphorylation at S62, and stabilization. The study therefore
identifies lncNB1, its binding protein RPL35 and their target
DEPDC1B as key factors in N-Myc-driven oncogenesis and as
therapeutic targets.
Results
LncNB1 is over-expressed in MYCN-amplified neuroblastoma.
To identify genes important for N-Myc-induced tumorigenesis, we
performed RNA sequencing analysis of four MYCN-amplified
[CHP134, SK-N-DZ, Kelly, and BE(2)-C] and two MYCN-non-
amplified (SK-N-AS and SY5Y) human neuroblastoma cell lines.
Differential expression analysis revealed 459 genes being differen-
tially expressed between the MYCN-amplified and non-amplified
samples (Supplementary Data 1).
Consistent with the literature16–18, MYCN-amplified neuro-
blastoma cell lines showed very high levels of N-Myc, MYCNOS,
and IGF2BP1 and very low levels of c-Myc RNA expression
(Fig. 1a, b). Interestingly, the lncRNA RP1-40E16.9 at chromo-
some 6: 3182817–3195767, also known as LOC100507194 and
LINC02525 but will herein be referred to as lncNB1 (lncRNA
highly expressed in neuroblastoma 1), was polyadenylated and
displayed an expression pattern very similar to N-Myc and
MYCNOS (Fig. 1a, b), suggesting that this lncRNA could be
involved in MYCN-amplified neuroblastoma tumorigenesis. The
other RNAs considerably over-expressed in MYCN-amplified
neuroblastoma cell lines were RP11-102F4.3, RNF217, GRIK3,
and SLCO5A1 (Fig. 1a, b).
The publicly available Genotype-Tissue Expression (GTEx)
Release V7 dataset (dbGaP Accession phs000424.v7.p2) provides
RNA sequencing transcript expression data from 53 non-diseased
tissues of different sites across nearly 1000 people. Analysis of the
GTEx Release V7 dataset showed that lncNB1 was expressed in
the brain, pituitary, testis, uterus, and nerve tissues, but hardly
detectable in other human tissues (Supplementary Fig. 1a). We
next examined lncNB1 expression in human tumor tissues of
various organ origins in The Cancer Genome Atlas (TCGA)
cohort. As shown in Fig. 1c, lncNB1 was most highly expressed in
a proportion of human neuroblastoma tumors, moderately
elevated in skin melanoma tissues, but considerably lower in
other cancer tissues.
Using the publicly available single-nucleotide polymorphism
array data from human neuroblastoma tissues, which were
originally generated by the Therapeutically Applicable Research
to Generate Effective Treatments (TARGET) initiative19, we
found that the lncNB1 gene was gained in six and deleted in 1 of
the 341 neuroblastoma tissue samples (Supplementary Table 1),
suggesting that lncNB1 gene copy number change was uncom-
mon in neuroblastoma.
By RT-PCR analysis, we confirmed that lncNB1 was expressed at
considerably higher levels in five MYCN-amplified, compared with
threeMYCN-non-amplified neuroblastoma cell lines (Fig. 1d). Using
the publicly available Maris-41-FPKM-rsg001 RNA sequencing
dataset from 39 human neuroblastoma cell lines [http://r2.amc.nl]20,
two-sided Pearson’s correlation study showed that lncNB1 RNA
expression positively correlated with N-Myc mRNA expression
(Fig. 1e), and lncNB1 was expressed at a significantly higher level in
a subset of human neuroblastoma tumors withMYCN amplification
(Fig. 1f). In addition, RT-PCR analysis showed that lncNB1 RNA
was mainly localized in the cytoplasm not in the nucleus
(Supplementary Fig. 1b, c).
Taken together, the data suggest that lncNB1 expression is the
highest in neuroblastoma compared with all other human cancers,
and correlates with MYCN gene amplification and expression.
LncNB1 up-regulates DEPDC1B gene and E2F1 protein
expression. LncRNAs are well-known to regulate the expression of
neighboring protein-coding genes10,21,22. Our RT-PCR analysis
showed that transfection of BE(2)-C and CHP134 neuroblastoma
cells, which express high levels of lncNB1 (Fig. 1d), with
lncNB1 siRNAs, siRNA-1, or siRNA-2, did not have an effect on
the expression of TUBB2A or TUBB2B (Supplementary Fig. 2a, b),
the neighboring protein-coding genes of lncNB1.
To examine the effect of lncNB1 in regulating gene expression
in trans, BE(2)-C cells were transfected with control siRNA,
lncNB1 siRNA-1, or siRNA-2 for 40 h. Affymetrix microarray
differential gene expression analysis revealed that knocking down
lncNB1 modulated the expression of a number of target genes
(Supplementary Table 2), among which DEPDC1B was a
potentially important candidate gene as it is known to induce
ERK protein phosphorylation23,24 and phosphorylated ERK is
known to enhance N-Myc protein stability3,4. Gene set enrich-
ment analysis showed that the most repressed transcription
factor-binding sites, after lncNB1 knockdown, were binding sites
for E2F1 and its partners E2F1-DP1 and E2F1-DP2 (Fig. 2a,
Supplementary Table 3). RT-PCR and immunoblot analyses
confirmed that lncNB1 siRNAs consistently reduced DEPDC1B
mRNA and protein as well as E2F1 protein, but did not show a
consistent effect on E2F1 mRNA, in BE(2)-C, Kelly and CHP134
neuroblastoma cells (Fig. 2b, c).
We next established BE(2)-C and Kelly cells stably expressing
doxycycline-inducible control shRNA, lncNB1 shRNA-1 or
lncNB1 shRNA-2, which targeted lncNB1 RNA regions different
from lncNB1 siRNAs. RT-PCR and immunoblot analyses
confirmed that treatment with doxycycline consistently reduced
lncNB1 and DEPDC1B mRNA as well as DEPDC1B and E2F1
protein but not E2F1 mRNA expression in doxycycline-inducible
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lncNB1 shRNA cells (Fig. 2d, e, Supplementary Fig. 2c). Taken
together, the data demonstrate that lncNB1 up-regulates
DEPDC1B gene expression and increases E2F1 protein expression.
LncNB1 up-regulates N-Myc protein expression through
DEPDC1B. N-Myc protein is stabilized after phosphorylation at
S62 by phosphorylated ERK3. Since DEPDC1B is known to induce
ERK protein phosphorylation24, we examined whether lncNB1
regulated ERK protein phosphorylation, N-Myc protein phos-
phorylation, and stabilization. Transfection with lncNB1 siRNAs
did not alter N-Myc mRNA expression (Supplementary Fig. 3a),
but considerably reduced DEPDC1B protein expression, ERK
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Fig. 1 LncNB1 is over-expressed inMYCN-amplified human neuroblastoma tissues and cells. a, b RNA was extracted from fourMYCN-amplified (BE(2)-C, Kelly,
CHP134, and SK-N-DZ) and two MYCN-non-amplified (SY5Y and SK-N-AS) neuroblastoma cell lines. Heatmap showed the top 40 genes most differentially
expressed between the two groups of cell lines (a). Volcano plot revealed the top genes most significantly differentially expressed between the cell lines with
the lowest false discovery rate (b). c lncNB1 RNA expression in human tumor tissues of various organ origins in The Cancer Genome Atlas (TCGA) cohort. The
center line was the median, the bounds of the box were the upper and lower quartiles and the whiskers extended to 1.5× the inter-quartile range. Abbreviations
of cancers were explained in the Methods section, and NB and SKCM represented neuroblastoma and skin melanoma. d RNA was extracted from MYCN-
amplified and MYCN-non-amplified human neuroblastoma cell lines, followed by RT-PCR analysis of lncNB1 RNA expression. Data were shown as the mean ±
standard error of three independent experiments. e, f lncNB1 and N-Myc RNA expression was extracted from the publicly available Maris-41-FPKM-rsg001 RNA
sequencing dataset from 39 human neuroblastoma cell lines downloaded from R2 microarray analysis and visualization platform [http://r2.amc.nl]. Correlation
between lncNB1 and N-Myc RNA expression was analyzed by two-sided Pearson’s correlation (e). The center line was the median, the bounds of the box were
the upper and lower quartiles, and the whiskers were set to the minimum and maximum values (p=0.001, two-sided unpaired Student’s t-test). Data were
shown as the mean ± standard error (f). Source data are provided as a Source Data file
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Fig. 2 LncNB1 is required for DEPDC1B mRNA and protein and E2F1 protein expression. a Genome-wide differential gene expression was examined with
Affymetrix microarray in BE(2)-C cells 40 h after transfection with control siRNA, lncNB1 siRNA-1, or siRNA-2. Gene set enrichment analysis generated
histograms confirming down-regulation of E2F1 target genes by lncNB1 siRNAs. FDR indicated false discovery rate. b, c BE(2)-C, Kelly, and CHP134 cells were
transfected with control siRNA, lncNB1 siRNA-1, or lncNB1 siRNA-2 for 48 h. LncNB1, DEPDC1B, and E2F1 RNA expression was analyzed by RT-PCR (b), and
DEPDC1B, E2F1, and N-Myc protein expression was analyzed by immunoblot (c). Data were shown as the mean ± standard error of three independent
experiments, and evaluated by one-way ANOVA. *, **, and *** indicate P < 0.05, 0.01, and 0.001 respectively. d, e Doxycycline (DOX)-inducible control shRNA,
lncNB1 shRNA-1 or shRNA-2 BE(2)-C (d) and Kelly (e) cells were treated with vehicle control or DOX for 48 h. RNA and protein were extracted from the cells
for RT-PCR and immunoblot analyses of lncNB1, DEPDC1B, E2F1, and N-Myc. Data were shown as the mean ± standard error of three independent experiments,
and evaluated by two-tailed unpaired Student’s t-test. *, **, and *** indicate P < 0.05, 0.01, and 0.001 respectively. Source data are provided as a Source Data file
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protein phosphorylation, N-Myc protein phosphorylation at S62 and
expression in BE(2)-C, Kelly, and CHP134 cells (Fig. 3a). Consistent
with these data, transfection with DEPDC1B siRNAs reduced
DEPDC1B but not N-Myc mRNA expression (Supplementary
Fig. 3b, c), and reduced DEPDC1B protein expression, ERK protein
phosphorylation, N-Myc protein phosphorylation at S62 and
expression in the three neuroblastoma cell lines (Fig. 3b). In addition,
transfection with a lncNB1 or DEPDC1B over-expression construct
in BE(2)-C and Kelly cells up-regulated DEPDC1B protein
expression, ERK protein phosphorylation as well as N-Myc protein
expression (Supplementary Fig. 3d). DOX-inducible lncNB1
shRNA BE(2)-C and Kelly cells were then transfected with an
empty vector or DEPDC1B expression construct and treated with
vehicle control or DOX for 48 h. Immunoblot analysis showed that
forced DEPDC1B over-expression largely reversed lncNB1 shRNA-
mediated ERK protein dephosphorylation, N-Myc protein depho-
sphorylation at S62, and N-Myc protein reduction (Supplementary
Fig. 3e).
BE(2)-C cells were then transfected with control siRNA,
lncNB1 siRNA-1, or DEPDC1B siRNA-1 for 30 h, followed by
treatment with vehicle control, the protein synthesis inhibitor
cyclohexamide, or the proteasome inhibitor MG-132. In addition,
BE(2)-C cells were transfected with an empty vector or lncNB1
expression construct, followed by treatment with vehicle control or
cycloheximide. The pulse chase assays showed that N-Myc protein
half-life was reduced by approximately 50% by lncNB1 siRNA or
DEPDC1B siRNA (Fig. 3c), and was increased by approximately
39% by the lncNB1 expression construct (Supplementary Fig. 3f).
While MG-132 did not increase DEPDC1B protein expression in
cells transfected with lncNB1 siRNA or DEPDC1B siRNA, which
ablated DEPDC1B mRNA, MG-132 dramatically up-regulated N-
Myc protein expression in cells transfected with lncNB1 siRNA or
DEPDC1B siRNA (Fig. 3d). The data demonstrate that lncNB1 and
DEPDC1B are required for N-Myc protein stability.
Stable doxycycline-inducible control shRNA, lncNB1 shRNA-1
or lncNB1 shRNA-2 BE(2)-C and Kelly cells were then treated
with vehicle control or doxycycline for 48 h. Immunoblot analysis
confirmed that knocking down lncNB1 reduced DEPDC1B and
N-Myc protein expression, ERK protein phosphorylation, and N-
Myc protein phosphorylation at S62 (Fig. 3e).
To exclude cell growth inhibition or cell death as a contributing
factor in the regulation of N-Myc expression, we transfected BE
(2)-C and Kelly cells with control siRNA, lncNB1 siRNAs or
DEPDC1B siRNAs for 48 h, and treated DOX-inducible control
shRNA and lncNB1 shRNA BE(2)-C and Kelly cells with vehicle
control or DOX for 48 h. Alamar blue assays and flow cytometry
analyses of Annexin V positively stained cells showed that
knocking down lncNB1 or DEPDC1B expression for 48 h was too
early to have an effect on neuroblastoma cell proliferation or
survival (Supplementary Fig. 4a–e). Taken together, the data
show that lncNB1 is required for N-Myc protein expression
through DEPDC1B gene transcription, ERK protein phosphor-
ylation, N-Myc protein phosphorylation at S62 and thus N-Myc
protein stability.
LncNB1 activates DEPDC1B gene transcription through E2F1.
To further investigate whether lncNB1 can regulate DEPDC1B
and E2F1 gene transcription, we performed chromatin immu-
noprecipitation (ChIP) assays with a control IgG or an antibody
against tri-methylated histone H3 lysine 4 (H3K4me3), a marker
for active gene transcription, followed by PCR with primers tar-
geting a negative control, the DEPDC1B or the E2F1 gene core
promoter region (Supplementary Fig. 5a). The ChIP assays
showed that knocking down lncNB1 reduced H3K4me3 at the
DEPDC1B, but not the E2F1, gene core promoter (Supplementary
Fig. 5b), further demonstrating that lncNB1 regulates DEPDC1B,
but not E2F1, gene transcription.
We then cloned the DEPDC1B gene promoter regions 1146,
545, or 75 bp upstream of the transcription start site into the pGL3
firefly-luciferase construct (Fig. 4a), and transfected the constructs
into doxycycline-inducible control shRNA, lncNB1 shRNA-1, or
lncNB1 shRNA-2 BE(2)-C cells. Dual luciferase assays showed
that knocking down lncNB1 expression with doxycycline
considerably reduced luciferase activity of all the wild type
constructs (Fig. 4a), suggesting that the 75 bp region upstream of
the DEPDC1B transcription start site was essential and sufficient
for lncNB1 to activate DEPDC1B gene transcription. As a 20 bp
nucleotide section in the 75 bp region was enriched of E2F1-
binding sites, we generated DEPDC1B gene promoter pGL3
constructs deleted of the 20 nucleotides (Fig. 4a). Dual luciferase
assays showed that deletion of the 20 nucleotides abolished the
effect of lncNB1 shRNAs in reducing DEPDC1B promoter activity
(Fig. 4a).
Since RT-PCR analysis showed that lncNB1 RNA was mainly
localized in the cytoplasm not in the nucleus (Supplementary
Fig. 1b, c), we investigated whether lncNB1 induced DEPDC1B
gene transcription via E2F1 activity. Knockdown of E2F1
expression with two independent siRNAs reduced DEPDC1B
mRNA and protein expression in both BE(2)-C and Kelly
neuroblastoma cell lines (Fig. 4b, c), and replicated the effects of
lncNB1 siRNAs, lncNB1 shRNAs, and DEPDC1B siRNAs in
reducing ERK protein phosphorylation, N-Myc protein phos-
phorylation at S62 and N-Myc protein expression in BE(2)-C and
Kelly cells (Supplementary Fig. 5c). ChIP assays showed that
E2F1 protein was highly enriched at the DEPDC1B gene core
promoter region close to the transcription start site, and that
knocking down lncNB1 expression with doxycycline considerably
reduced E2F1 protein binding at the DEPDC1B gene core
promoter in doxycycline-inducible lncNB1 shRNA-1 and
shRNA-2 BE(2)-C cells (Fig. 4d). Moreover, luciferase assays
showed that forced over-expression of E2F1 and its functional
partner DP1 significantly enhanced wild-type DEPDC1B gene
promoter activity, and that the effect was abolished by deletion of
the E2F1-binding site-enriched 20 nucleotides of the DEPDC1B
gene promoter (Fig. 4e). Taken together, the data indicate that
lncNB1 activates DEPDC1B gene transcription through increas-
ing E2F1 protein expression.
LncNB1 induces E2F1 protein translation by binding to
RPL35. To identify the mechanism by which lncNB1 increases
E2F1 protein but not mRNA expression, we in vitro-transcribed
lncNB1 RNA from full-length lncNB1 cDNA products containing
the T7 promoter in the sense strand (experimental) or SP6 pro-
moter in the antisense strand (negative control) and labeled the
RNA with biotin. The biotin-labeled lncNB1 RNA was then incu-
bated with protein lysates from BE(2)-C and Kelly cells. Mass
spectrometry analysis showed that lncNB1 RNA specifically bound
to ribosomal protein L35 (RPL35), the RNA helicase DDX42, the
histone protein H1X, interleukin enhancer-binding factor 2 (ILF2),
and heterogeneous nuclear ribonucleoprotein K (HNRPK) proteins
in both BE(2)-C and Kelly cells (Supplementary Table 4).
We then employed siRNAs to knock down RPL35, DDX42,
H1X, ILF2, and HNRPK in Kelly cells, and found that only
knocking down RPL35 significantly down-regulated DEPDC1B,
N-Myc, and E2F1 protein expression (Fig. 5a, Supplementary
Fig. 6a–c). RT-PCR analysis further showed that knocking down
RPL35 with two independent siRNAs significantly reduced
DEPDC1B, but not N-Myc and E2F1, mRNA expression
(Supplementary Fig. 6c). Immunoblot analysis demonstrated that
RPL35 siRNAs consistently reduced E2F1 and DEPDC1B protein
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expression, ERK protein phosphorylation, N-Myc protein
phosphorylation at S62 and expression (Fig. 5a). RNA immuno-
precipitation assays showed that an anti-RPL35 antibody,
compared with a control rabbit IgG, efficiently pulled down
RPL35 protein in BE(2)-C and Kelly cells (Fig. 5b), that RPL35
bound to lncNB1 RNA and E2F1 RNA (Fig. 5c, d), and that
transfection with lncNB1 siRNA-1 or siRNA-2 reduced RPL35
protein binding to E2F1 RNA (Fig. 5d).
BE(2)-C and Kelly cells were next transfected with control
siRNA, lncNB1 siRNAs, or RPL35 siRNAs, followed by puromycin
incorporation assays for measuring protein synthesis25. Immuno-
precipitation with an anti-puromycin antibody showed that
the anti-puromycin antibody efficiently immunoprecipitated
puromycin-labeled proteins, that lncNB1 siRNAs reduced the
synthesis of E2F1 protein but not global proteins (Fig. 5e), and
that RPL35 siRNAs considerably reduced the synthesis of
proteins globally, including E2F1 protein (Fig. 5f). BE(2)-C cells
were then transfected with control siRNA, lncNB1 siRNA-1, or
lncNB1 siRNA-2, followed by cycloheximide treatment and
polysome fractionation. Polysome profiling and RT-PCR showed
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that lncNB1 knockdown shifted E2F1 mRNA (Fig. 5g), but not
N-Myc mRNA (Supplementary Fig. 6d), from heavy polysomes
to light polysomes, indicating reduced E2F1 mRNA translation.
In addition, Affymetrix microarray experiments revealed that
lncNB1 knockdown resulted in reduction in the expression of 34
mRNAs, including E2F1 mRNA, in the heavy polysomes
(Supplementary Table 5), and fluorescence in situ hybridization
and immunocytochemistry double labeling experiments showed
that lncNB1 RNA and RPL35 protein were mostly located in the
cytoplasm in neuroblastoma cells (Supplementary Fig. 7a, b).
Taken together, the data demonstrate that lncNB1 increases
E2F1 protein expression by binding to the ribosomal protein
RPL35, leading to E2F1 protein synthesis and DEPDC1B gene
transcription.
LncNB1 induces neuroblastoma cell proliferation and survival.
We next investigated if lncNB1, DEPDC1B, RPL35, or E2F1 is
required for neuroblastoma cell proliferation and/or survival. BE
(2)-C, Kelly, and CHP134 cells were transfected with control
siRNA, lncNB1 siRNA-1, or lncNB1 siRNA-2. Alamar blue assays
showed that knocking down lncNB1 expression reduced the
numbers of viable cells (Fig. 6a), BrdU incorporation assays showed
that lncNB1 knockdown consistently reduced neuroblastoma cell
proliferation (Supplementary Fig. 8), and flow cytometry analysis of
Annexin V positively stained cells showed that knocking down
lncNB1 induced apoptosis (Fig. 6b), suggesting that lncNB1 is
required for neuroblastoma cell proliferation and survival. Con-
sistent with the data from lncNB1 siRNAs, transfection with
DEPDC1B siRNAs, RPL35 siRNAs, or E2F1 siRNAs (Fig. 6c–e)
also reduced the number of viable BE(2)-C and Kelly cells.
Doxycycline-inducible control shRNA, lncNB1 shRNA-1 or
shRNA-2 BE(2)-C and Kelly cells were then treated with vehicle
control or doxycycline, followed by analysis of the cell cycle and
apoptosis. Cell cycle analysis showed that knocking down lncNB1
with doxycycline consistently reduced the percentage of neuro-
blastoma cells at the S phase (Fig. 6f), and apoptosis analysis
showed that knocking down lncNB1 resulted in apoptosis (Fig. 6g).
Taken together, the data suggest that lncNB1, its binding partner
RPL35 and their targets E2F1 and DEPDC1B are required for
neuroblastoma cell proliferation and survival.
LncNB1 knockdown leads to neuroblastoma regression in
mice. We next examined whether lncNB1 is essential for neuro-
blastoma cell clonogenic capacity in vitro and tumor progression
in vivo. Doxycycline-inducible control shRNA, lncNB1 shRNA-1
or lncNB1 shRNA-2 BE(2)-C and Kelly cells were treated with
vehicle control or doxycycline. Clonogenic assays showed that
treatment with doxycycline did not have an effect on colony
formation in doxycycline-inducible control shRNA cells, but
almost completely abolished and indeed completely abolished
clonogenic capacity of doxycycline-inducible lncNB1 shRNA-1
and lncNB1 shRNA-2 BE(2)-C and Kelly cells, respectively
(Fig. 7a, b), suggesting that lncNB1 plays a critical role in neu-
roblastoma tumorigenesis.
Doxycycline-inducible lncNB1 shRNA-1 BE(2)-C cells were
then xenografted into nude mice. When tumors reached 50 mm3,
the mice were divided into two groups, and fed with food with or
without doxycycline. As shown in Fig. 7c, d, treatment with
doxycycline, compared with vehicle control, significantly sup-
pressed neuroblastoma progression. The tumors shrunk over the
first 10 days in all mice, then stabilized at approximately 220 mm3
in one mouse and completely regressed in four out of ten mice,
over a period of 6 months. Survival curve showed that knocking
down lncNB1 considerably improved mouse overall survival.
These results therefore demonstrate that lncNB1 plays an
essential role in MYCN-amplified neuroblastoma tumorigenesis.
High lncNB1 in tumor tissues predicts poor patient prognosis.
To assess the clinical relevance of the above findings, we examined
lncNB1, DEPDC1B, RPL35, and E2F1 expression in 493 human
neuroblastoma tissues in the publicly available neuroblastoma
tissue RNA sequencing-patient prognosis SEQC-RPM-seqcnb1
dataset downloaded from the R2 platform [http://r2.amc.nl] (last
accessed on 26 August 2016)26. Five out of 498 samples were
excluded from analysis, due to the lack of information on MYCN
amplification status. Two-sided Pearson’s correlation study and
Student’s t-test showed that lncNB1 RNA expression positively
correlated with MYCN amplification (Fig. 8a), N-Myc mRNA
expression (Supplementary Fig. 9a) as well as DEPDC1B mRNA
expression (Fig. 8b), and that RPL35 and E2F1 mRNA expression
also positively correlated with DEPDC1B mRNA expression in the
493 human neuroblastoma tissues (Fig. 8c, d).
Using the median level of RNA expression as the cut-off point,
Kaplan–Meier survival analysis showed that high levels of
lncNB1, DEPDC1B, RPL35, and E2F1 RNA expression in the
493 neuroblastoma tissues of the SEQC-RPM-seqcnb1 dataset
were associated with poor patient prognosis (Fig. 8e–h). In
addition, high levels of lncNB1, DEPDC1B, RPL35, or E2F1 RNA
expression in 181 stage 4 neuroblastoma tissues of the SEQC-
RPM-seqcnb1 dataset were also associated with poor patient
prognosis (Fig. 8i–l). Consistent with these data, high levels of
lncNB1, DEPDC1B, RPL35, or E2F1 RNA expression in 88
neuroblastoma tissues of the much smaller publicly available
microarray gene expression-patient prognosis Versteeg dataset,
which was also downloaded from the R2 platform, were
also associated with poor patient prognosis (Supplementary
Fig. 9b–e).
Fig. 4 LncNB1 activates DEPDC1B gene transcription through the transcription factor E2F1. a Wild type and E2F1-binding site deletion mutant (Δ20bp)
DEPDC1B gene promoters were cloned into a pGL3 firefly-luciferase (Firefly_LUC) construct. DOX-inducible control shRNA, lncNB1 shRNA-1, and lncNB1
shRNA-2 BE(2)-C cells were transfected with the wild type or Δ20bp deletion mutant DEPDC1B gene promoter pGL3 constructs, followed by treatment
with vehicle control or DOX and luciferase assays. Percentage change in luciferase activity, measured as relative light unit (RLU) due to DOX treatment as
compared with vehicle control treatment, was normalized by the luciferase activity of DOX-inducible control shRNA cells treated with vehicle control. Data
were shown as the mean ± standard deviation, and evaluated by one-way ANOVA. *, **, and *** indicated P < 0.05, 0.01, and 0.001 respectively. b, c BE(2)-
C and Kelly cells were transfected with control siRNA, E2F1 siRNA-1, or E2F1 siRNA-2 for 48 h, followed by RT-PCR analysis of DEPDC1B (b) and
immunoblot analysis of DEPDC1B, E2F1, and N-Myc (c). Data were shown as the mean ± standard error of three independent experiments, and evaluated
by one-way ANOVA. *, **, and *** indicated P < 0.05, 0.01, and 0.001 respectively. d ChIP assays were performed with a specific anti-E2F1 antibody (Ab) in
DOX-inducible lncNB1 shRNA-1 or shRNA-2 BE(2)-C cells after treatment with vehicle control or DOX, followed by PCR with primers targeting different
regions of the DEPDC1B gene promoter (−600 bp, transcription start site (TSS) or +600 bp). e BE(2)-C cells were co-transfected with pCMV14-empty
vector or pCMV14-E2F1 plus pCMV10-3 × Flag-DP1 constructs in combination with wild type or E2F1-binding site (Δ20bp) deletion mutant DEPDC1B gene
promoter pGL3 Firefly_LUC construct. In d, e data were shown as the mean ± standard deviation of three independent experiments, and evaluated by two-
sided unpaired Student’s t-test. ** and *** indicated P < 0.01 and 0.001, respectively. Source data are provided as a Source Data file
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light polysomes. In c, d, g data were shown as the mean ± standard error of three or four independent experiments, and evaluated by two-sided unpaired
Student’s t-test or one-way ANOVA. *, **, and *** indicate P < 0.05, 0.01, and 0.001, respectively. Source data are provided as a Source Data file
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Taken together, the data suggest that lncNB1, RPL35, and E2F1
regulate DEPDC1B expression in human neuroblastoma tissues,
and that high levels of lncNB1, DEPDC1B, RPL35, and E2F1
expression in tumor tissues predict poor prognosis in neuro-
blastoma patients.
Discussion
Protein-coding genes important for c-Myc and N-Myc-induced
tumorigenesis have been the focus of intense research in the
past three decades. In comparison, little is known about
lncRNAs in Myc-induced carcinogenesis. Here our RNA
sequencing analysis identifies N-Myc, MYCNOS, IGF2BP1,
lncNB1, RNF217, RP11-102F4.3, GRIK3, and SLCO5A1 as the
RNAs most considerably over-expressed in MYCN-amplified,
compared with MYCN-non-amplified, neuroblastoma cell lines.
MYCNOS18 and IGF2BP116 promote MYCN-driven neuro-
blastoma metastasis and tumorigenesis, respectively, RNF21727,
GRIK328, and SLCO5A129 promotes leukemia, breast and colon
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cancer. However, the lncRNAs lncNB1 and RP11-102F4.3 have
never been studied in normal physiology or disease. Analysis of
TCGA datasets with more than 10,000 human tumor tissues of
various organ origins shows that lncNB1 is most abundantly
over-expressed in human neuroblastoma tissues, suggesting a
role of lncNB1 in neuroblastoma tumorigenesis.
LncRNAs are emerging as critical regulators of gene expression
through transcriptional, post-transcriptional and post-translational
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mechanisms. For example, several sense lncRNAs up-regulate the
transcription of their neighboring protein-coding genes through
interacting with the histone H3K4 methylation adaptor WDR5 or
the transcriptional co-activator mediator10,22,30, whereas the
lncRNA NORAD sequesters PUMILIO proteins for genomic sta-
bility14. In this study, our genome-wide differential gene expression
and gene set enrichment analysis show that knocking down lncNB1
considerably reduces E2F1 signaling activity and the expression of
DEPDC1B, which is known to induce ERK protein phosphoryla-
tion24. While N-Myc protein is well-known to be stabilized after
phosphorylation at S62 by phosphorylated ERK protein3,4, we have
found that knocking down lncNB1 or DEPDC1B consistently
reduces DEPDC1B mRNA and protein expression, ERK protein
phosphorylation, N-Myc protein phosphorylation at S62, expres-
sion and half-life, while N-Myc mRNA expression is not altered.
Additionally, forced DEPDC1B over-expression reverses ERK
protein dephosphorylation, N-Myc protein dephosphorylation at
S62, and N-Myc protein reduction due to lncNB1 knockdown. Our
data therefore suggest that lncNB1 up-regulates N-Myc protein
expression through inducing DEPDC1B gene expression, leading to
ERK protein phosphorylation and N-Myc protein stabilization, and
that lncNB1 and DEPDC1B are factors important for N-Myc
protein stability.
In this study, our RNA fractionation experiments show that
lncNB1 RNA is located predominantly in the cytoplasm, sug-
gesting that lncNB1 indirectly induces DEPDC1B gene tran-
scription. Luciferase assays show that a 20 bp region enriched of
E2F1-binding sites at the DEPDC1B gene core promoter is
essential for lncNB1-induced DEPDC1B gene promoter activity,
that E2F1 directly induces DEPDC1B gene promoter activity, and
that the effect of E2F1 is abolished when the 20 bp region enri-
ched of E2F1-binding sites is deleted. In concordance, ChIP
assays confirm that E2F1 protein binding to the DEPDC1B gene
core promoter is reduced with lncNB1 knockdown. Moreover,
E2F1 siRNAs reduce DEPDC1B mRNA and protein expression
and replicate the effects of lncNB1 and DEPDC1B siRNAs on
ERK phosphorylation, N-Myc protein phosphorylation and
expression. These data therefore suggest that lncNB1 indirectly
induces DEPDC1B gene transcription through increasing protein
expression of E2F1, which directly binds to the DEPDC1B gene
promoter and enhances DEPDC1B gene transcription, leading to
ERK protein phosphorylation and N-Myc protein stabilization.
Our RNA-binding protein pull-down and mass spectrometry
analyses have identified the ribosomal protein RPL35, a compo-
nent of the 60S ribosomal subunit, as one of the few proteins
bound to lncNB1 RNA. In the literature, 60S ribosomal subunit
proteins play key roles in mRNA translation and protein synth-
esis. For example, as a regulatory component of the ribosome,
RPL13 binds to Rig-I and controls NF-κb protein synthesis31, and
RPL38 facilitates 80S complex formation on a select subset of
Homeobox mRNAs to confer transcript-specific translational
control32,33. RPL35 has recently been found to interact with
eukaryotic translation elongation factor 2 and thereby control
CSN2 protein synthesis34. In this study, our puromycin incor-
poration and polysome profiling assays demonstrate that
knocking down lncNB1 considerably reduces E2F1 protein
synthesis, and that knocking down RPL35 globally reduces pro-
tein synthesis. In addition, RPL35 siRNAs replicate the effects of
lncNB1 siRNAs, DEPDC1B siRNAs, and E2F1 siRNAs on
DEPDC1B expression, ERK protein dephosphorylation, N-Myc
protein dephosphorylation at S62, and N-Myc protein reduction.
Our data therefore suggest that lncNB1 RNA binds to RPL35
protein to facilitate E2F1 protein synthesis, leading to DEPDC1B
gene transcription, ERK protein phosphorylation and consequent
N-Myc protein phosphorylation at S62 and stabilization.
The role of the lncRNA lncNB1 in cancer or normal physiology
is completely unknown. RPL35 has recently been found to be
over-expressed in human colorectal cancer tissues with unknown
functions35. We have found that knocking down lncNB1
expression results in neuroblastoma cell growth inhibition and
apoptosis, abolishes neuroblastoma cell clonogenic capacity
in vitro, and leads to tumor regression in neuroblastoma-bearing
mice. Consistent with these data, DEPDC1B, E2F1, and RPL35
are also required for neuroblastoma cell proliferation and/or
survival. In addition, in human neuroblastoma tissues, lncNB1,
E2F1, or RPL35 RNA expression positively correlates with
DEPDC1B RNA expression, and high levels of lncNB1, E2F1,
RPL35, or DEPDC1B expression predict poorer patient outcome.
Thus, our data demonstrate that lncNB1, its binding protein
RPL35 and their target protein E2F1 and target gene DEPDC1B
induce neuroblastoma cell proliferation and survival. As high
levels of lncNB1, RPL35, E2F1, and DEPDC1B expression in
tumor tissues correlate with poor prognosis in neuroblastoma
patients, our findings identify lncNB1, RPL35, and DEPDC1B as
important co-factors for N-Myc-driven oncogenesis and provide
therapeutic targets for neuroblastoma.
Methods
Cell culture. Neuroblastoma BE(2)-C, IMR32, SY5Y, and SHEP cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf
serum. SK-N-DZ and SK-N-AS cells were cultured in DMEM supplemented with
10% fetal calf serum and 1% non-essential amino acids. Kelly and CHP134 cells
were cultured in Roswell Park Memorial Institute Medium (RPMI) 1640 supple-
mented with 10% fetal calf serum and 1% L-glutamine. BE(2)-C, SHEP, and SY5Y
cells were provided by Barbara Spengler (Fordham University, New York, NY) 20
years ago. IMR32 were obtained from the American Type Culture Collection
(Manassas, VA) 20 years ago. The Lenti-X™ 293T viral packaging cell line was
purchased from Scientifix (South Yarra, Victoria, Australia). Kelly, CHP134, SK-N-
DZ, and SK-N-AS cells were obtained from the European Collection of Cell Cul-
tures through Sigma in 2010 (Sigma, Sydney, Australia). All cell lines were
maintained in a humidified incubator at 37 °C and 5% CO2 in air. The identity of
cell lines was verified in 2010, 2014, 2015, 2016, 2017, and 2018 by short tandem
repeat profiling conducted at the Garvan Institute of Medical Research or Cellbank
Australia.
Doxycycline-inducible shRNA expression cell lines. The lentiviral doxycycline-
inducible GFP-IRES-shRNA FH1tUTG construct from Dr. Marco Herold36 was
used to generate control shRNA and lncNB1 shRNA expressing constructs as well
as neuroblastoma cell lines stably expressing the constructs. lncNB1 shRNA target
sequences were GCTGCAGCGTTTACCCAAAGA (shRNA-1) and GCTTCCTT
CAAACCTCAAATC (shRNA-2) (Supplementary Table 6). Sense and antisense
shRNA oligoes were synthesized by GeneWorks (Thebarton, SA, Australia), and
cloned into the doxycycline-inducible GFP-IRES-shRNA FH1tUTG construct. The
doxycycline-inducible GFP-IRES-control shRNA, lncNB1 shRNA-1, or lncNB1
shRNA-2 FH1tUTG construct was transfected into 293T cells. Viral media were
collected and employed to infect neuroblastoma cells with polybrene (Santa Cruz
Biotechnology, Santa Cruz, CA) for 72 h. Fluorescence-activated cell sorting was
performed with BD FACS Jazz™ II Cell Sorter (BD Biosciences, Franklin Lakes, NJ)
to select neuroblastoma cells with high GFP protein expression. Cells were treated
with 2 µg/ml doxycycline (Sigma) or DMSO vehicle control every 24 h to or to not
induce shRNA expression.
siRNA transfection. Target sequences of siRNAs were 5′-CAGCTGCAGCGTTT
ACCCAAA-3′ (siRNA-1) and 5′-CACAGCGAATGCTAACTGATA-3′ (siRNA-2)
(Qiagen, Hamburg, Germany) for lncNB1; 5′-GAGGAGCGTGTGGCTCATCTA-
3′ (siRNA-1) (Qiagen) and 5′-GAGTTATTAGCTGCTAGATTGGTAA-3′
(siRNA-2) (Invitrogen, Carlsbad, CA) for DEPDC1B; 5′-CGTGCCGGAGTTGGT
AAAGAA-3′ (siRNA-1) and 5′-TCCAGCGAGCTGATCCTCAAA-3′ (siRNA-2)
(Qiagen) for N-Myc; 5′-TGGCATTTGTATTGATAGTTA-3′ (siRNA-1) and 5′-
TATGTTAGTTGTGAAGAACTA-3′ (siRNA-2)(Qiagen) for HNRPK; 5′-CTC
CATAGAAGTGTCATTCCA-3′ (siRNA-1) and 5′-CAGGCCCTTTGTACCACA
TAT-3′ (siRNA-2) (Qiagen) for ILF2; 5′-CTCGTCGCTGGCCAAGATCTA-3′
(siRNA-1) and 5′-CGCCGAGGGAATGGCCAAGAA-3′ (siRNA-2) (Qiagen) for
H1X; 5′-CCCGGCGTCTGGTAGAATTTA-3′ (siRNA-1) and 5′-TACTAAGG
TGTCACCTTATTA-3′ (siRNA-2) for DDX42; 5′-CAGGACCTTCGTAGCAT
TGCA-3′ (siRNA-1) and 5′-CTCACTGAATCTGACCACCAA-3′ (siRNA-2) for
E2F1; 5′-CCGTGTTCTCACAGTTATTAA-3′ (siRNA-1) and 5′-TGCAGCAAT
GGCCAAGATCAA-3′ (siRNA-2) for RPL35 (Supplementary Table 6). Negative
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12971-3 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5026 | https://doi.org/10.1038/s41467-019-12971-3 | www.nature.com/naturecommunications 13
control siRNAs did not target any human genes (All Stars Negative Control siRNA,
Qiagen).
Neuroblastoma cells were transfected with siRNAs using Lipofectamine 2000
(Life Technologies, Grand Island, NY) according to the manufacturer’s instructions
and plated onto either 24- or 6-well plates or T25 flasks. Transfected cells were
harvested for either RNA or protein for analysis.
Plasmid transfection. The pCMV6-Entry lncNB1 expression construct was cus-
tom synthesized by Origene (Origene, Rockville, MD). DP1 cDNA was amplified
from BE(2)-C cells with Herculase II TAQ polymerase (Agilent Technologies,
Santa Clara, CA) using the following primers: TTTAAGCTTgcaaaagatgccggtcta
attgaag (forward); TTTTCTAGAgtcgtcctcgtcattctcgttg (reverse). E2F1 coding
sequence was amplified from the HA-E2F1 pRcCMV construct (Addgene plasmid
#21667)37, using the following primers: TTTAAGCTTatggccttggccggggcccctg
(pCMV14-HindIII E2F1 forward) and TTTGAATTCtcagaaatccaggggggtgaggt
ccccaaag (pCMV14-ECORI E2F1 reverse). PCR amplicons were then cloned into
pCMV10 or pCMV14 (Sigma, St Louis, MO), respectively, to generate
pCMV10_3× Flag-DP1 and pCMV14_E2F1 constructs. Cells were transiently
transfected with constructs using Lipofectamine 2000 reagent according to the
manufacturer’s protocol.
Real-time reverse transcription PCR (RT-PCR). RNA was extracted from cells
with RNeasy Plus minikit (Qiagen) and quantified with a Nanodrop spectro-
photometer (Thermo Fisher Scientific, Waltham, MA), according to the manu-
facturer’s instructions. cDNAs were then synthesized with Moloney murine
leukemia virus reverse transcriptase (Invitrogen) and random hexonucleotide
primers. RT-PCR was performed using gene- specific primers and Power SYBR
Green Master Mix (Invitrogen) as the fluorescent dye in Applied Biosystems 7900
(Applied Biosystems, Grand Island, NY). No template controls were used to detect
any non-specific amplification. The sequences of RT-PCR primers were 5′-CGACC
ACAAGGCCCTCAGTA-3′ (forward) and 5′-CAGCCTTGGTGTTGGAGGAG-3′
(reverse) for N-Myc; 5′-AATACGCCAATGTCCTGCTC-3′ (forward) and 5′-TCA
GTGCCTTGGCTTGTAGA-3′ (reverse) for lncNB1; 5′-AGCCTTGTTGGAGGAA
GTCA-3′ (forward) and 5′-TTTCGGTTTGGGTTTTTCAG-3′ (reverse) for
DEPDC1B; 5′-AATGAGGCTGCTGGTAACAAA-3′ (forward) and 5′-AAGGGTC
CAGACCTGACAGA-3′ for TUBB2A; 5′-AGGACGGACAGACCCAGAC-3′
(forward) and 5′-CAATCCCATGCTCATCACTG-3′ (reverse) for TUBB2B; 5′-TC
CGAATCCTCTCACATGGT-3′ (forward) and 5′-CCTTCTTCTCTGGTGGC
TTC-3′ (reverse) for ILF2; 5′-GACGGCATGGTTGGTTTCA-3′ (forward) and 5′-
ATTCTGATGGGCTCCATGTATCTAT-3′ (reverse) for HNRPK; 5′-TGGGC
GCACCTACCTCAA-3′ (forward) and 5′-CCTGCAGAAGCGTGTCGTT-3′ for
H1X; 5′-TGAGAACATGGATCGAGGAAATAA-3′ (forward) and 5′-TCTCCC
ATAGCTCCTGTGGAA-3′ for DDX42; 5′-GGACTCTTCGGAGAACTTTCAG
AT-3′ (forward) and 5′-GGGCACAGGAAAACATCGAT-3′ (reverse) for E2F1;
5′-CGGTGCGGCCTCCAA-3′ (forward) and 5′-CACGGGCAATGGATTTCC-3′
(reverse) for RPL35; 5′-AGGCCAACCGCGAGAAG-3′ (forward) and 5′-ACAGC
CTGGATAGCAACGTACA-3′ (reverse) for Actin. All primers were synthesized
by Sigma (Sigma, Sydney, Australia). Following RT-PCR, the comparative
threshold cycle (▵▵Ct) method38 was used to evaluate fold changes in target genes,
relative to the reference gene actin.
Immunoblot. Protein was extracted in RIPA buffer (150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-Cl pH 7.5) containing protease
inhibitors (Sigma, St Louis, MO) and phosphatase inhibitors (Roche, Penzberg,
Germany). After centrifugation at 13,000 × g at 4 °C for 20 min, supernatant was
collected. Protein was quantified with the Bicinchoninic Acid Assay kit (Pierce,
Rockford, IL). For immunoblot analysis, protein samples were loaded onto sodium
dodecyl sulfate-polyacrylamide gels, followed by electrophoresis and transfer to
nitrocellulose membranes. Membranes were blocked with 10% skim milk powder
in phosphate-buffered saline (PBS), and probed with the following primary anti-
bodies: rabbit anti-DEPDC1B (1:500) (HPA038255; Sigma), rabbit anti-S62-
phospho N-Myc (1:500) (A300-206A; Bethyl Laboratories, Montgomery, TX),
rabbit anti-T58-phospho c-Myc (1:2000) (ab28842; Abcam, Cambridge, MA),
mouse anti-N-Myc (1:1000) (sc-53993; Santa Cruz Biotechnology), rabbit anti-p-
p44/42 MAPK (T202/Y204) (phos-ERK) (1:500) (9101S; Cell Signalling, Danvers,
MA) or (1:500) (ab50011; Abcam), rabbit anti-p44/42 MAPK (ERK) (1:500)
(9102S; Cell Signalling), rabbit anti-RPL35 (1:500) (ab209087 or ab121244;
Abcam), or rabbit anti-E2F1 (1:1000) (3742S; Cell Signalling). The membranes
were then incubated with a goat anti-rabbit (sc-2004) or goat anti-mouse (sc-2005)
antibody conjugated to horseradish peroxidase (1:10,000) (both from Santa Cruz
Biotechnology), and protein bands were visualized with ECL (Biorad, Hercules,
CA). The membranes were finally probed with an anti-actin antibody (1:15000)
(A5441; Sigma) as loading controls.
RNA-binding protein pull-down assays. pCMV6-entry lncNB1 expression con-
struct was custom synthesized by OriGene, digested, and the linearized product
was purified using Qiagen PCR purification Kit (Qiagen). Full-length lncNB1 was
synthesized using primers containing the T7 promoter sequence in the forward
primer (taatacgactcactatagggagaTTCCTGTCATGTGAAACATG) and SP6
promoter sequence in the reverse primer (atttaggtgacactatagaagggGGCCAA-
CAACTGTTTAATG) with pCMV6-entry lncNB1 expression construct as tem-
plates. The full-length lncNB1 cDNA containing the T7 and SP6 promoters was
in vitro transcribed into sense (experimental) or antisense lncNB1 RNA (negative
control) with the Biotin RNA Labeling Mix kit (Roche) and T7 or SP6 polymerase,
respectively. The in vitro-transcribed sense and antisense lncNB1 RNAs were
treated with DNase I and purified with the RNeasy kit (Qiagen). Approximately
2 × 107 BE(2)-C and Kelly cells were harvested by scraping and resuspended in
1.2 ml of lysis buffer [150 mM NaCl, 50 mM Tris-Cl pH 7.5, 0.5% Triton X-100, 1×
protease inhibitor cocktail and 100 U/ml of SUPERaseIN (Thermo Fisher Scien-
tific)]. The cell lysate was sonicated using Bioruptor (Diagenode, Liege, Belgium)
for 10 min with 30 s on/off cycles and centrifuged for 10 min at 4 °C at maximum
speed. The protein lysate was pre-cleared with 50 µl of activated BcMag Monomer
Avidin Magnetic beads (Bioclone, San Diego, CA), according to the manufacturer’s
protocol. Ethylenediaminetetraacetic acid was added to 20 µg of biotin-labeled
sense or antisense lncNB1 RNA to a final concentration of 5 mM. The mixture was
heated to 90 °C in RNA structure buffer (10 mM Tris pH 7, 0.1 KCl, 10 mM
MgCl2) for 2 min, and cooled at room temperature for 20 min to allow
proper secondary structure formation. The biotin-labeled sense or antisense
lncNB1 RNA was then added to the pre-cleared protein lysate and incubated
overnight at 4 °C with rotation. Proteins which bound to sense or antisense lncNB1
RNA were isolated with BcMag Monomer Avidin Magnetic beads according to the
manufacturer’s protocol. The eluted proteins were examined by mass spectrometry
and analyzed using label-free quantification in Scaffold 4. Candidate proteins were
defined as those that were detectable with a minimum of two peptides in at least
two experimental repeats in both BE(2)-C and Kelly cells, with at least 2.5-fold
enrichment compared to the control antisense lncNB1 RNA pull down.
A immunoprecipitation assays. RNA immunoprecipitation assays were per-
formed using Magna RIP Kit from Merck Millipore (Burlington, MA) according to
the manufacturer’s instructions, with 5 μg of control IgG or anti-RPL35 antibody
(Abcam ab209087) for immunoprecipitation and primers targeting lncNB1 (5′-AA
TACGCCAATGTCCTGCTC-3′ as the forward primer and 5′-TTTCCAGTGT
CCTTCGAACC-3′ as the reverse primer), the positive control U1 SNRNP70 or the
negative control U1 RNAs for RT-PCR.
Affymetrix microarray gene expression study. BE(2)-C cells were transfected
with control siRNA, lncNB1 siRNA-1 or lncNB1 siRNA-2. Forty hours later, RNA
was extracted from the cells with RNeasy Mini kit (Qiagen), and four replicates of
differential gene expression was examined using Affymetrix Arrays (Affymetrix,
Santa Clara, CA)39 under two platforms (three replicates from HuGene-2_0-st and
one from Clariom_S_Human). Results from the microarray experiment from the
two platforms were analyzed in R [http://www.r-project.org/] with the bio-
conductor package [http://www.bioconductor.org/], and normalized with RMA
method (from R package oligo, Version 1.42.0) independently. Then, the meta-
analysis was implemented with the R package RankProd40,41 to do the downstream
differential expression analysis based on the combined normalized data. Gene set
enrichment analysis (GSEA) was conducted with the R package fgsea based on the
results generated from RankProd42 [pathway analysis against molecular signature
database C3: Motif gene sets (Broad Institute, Cambridge, MA)]. The genes were
ranked with the log2 fold change values, and the false discovery rate-adjusted
P values were computed with the Benjamini–Hochberg method42.
In addition, BE(2)-C cells were transfected with control siRNA, lncNB1 siRNA-
1 or lncNB1 siRNA-2 for 48 hours, followed by treatment with 50 µg/ml of
cycloheximide and polysome fractionation. RNA was extracted from the heavy
polysome and subjected to Clariom_S_Human Affymetrix Array experiments
(Affymetrix, Santa Clara, CA)39. Results from the microarray experiment were
analyzed in R [http://www.r-project.org/] with bioconductor package [http://www.
bioconductor.org/], and normalized with the RMA method (from R package oligo,
version 1.42.0). The downstream differential expression analysis was conducted
with the Limma package (version 3.34.9).
RNA extraction and sequencing. RNA was extracted from six human neuro-
blastoma cell lines [BE(2)-C, Kelly, CHP134, SK-N-DZ, SK-N-AS and SY-5Y]
using Direct-zol™ RNA kit (Zymo Research, Irvine, CA), purified with RNeasy Plus
Mini kit (Qiagen), and removed of ribosomal RNA with Ribo-Zero™ rRNA
Removal Magnetic kit (Illumina, San Diego, CA). RNA yield and quality were
measured with a BioSpec-nano spectrophotometer (Shimadzu Scientific Instru-
ments, Kyoto, Japan), and integrity was confirmed with Bioanalyzer separation
chips (Agilent Technologies) with A260/A280 ratios of >2.0 for all samples and a
minimum RNA Integrity Number (RIN) of 6.
One hundred nanograms of ribosome-depleted RNA was used as input to the
TruSeq mRNA Sample Prep v2 kit (Illumina), without the poly-A pulldown step.
Sample preparation was performed according to the manufacturer’s instructions
but starting with a 94 °C incubation at 2 min to elute, fragment and prime the RNA
samples. PCR cycles were reduced from 15 to 12 cycles to minimize the duplication
rate. The libraries were multiplexed into one lane and sequenced on a HiSeq2000
(Illumina) using TruSeq SBS Kit v3 kit (Illumina) and 100 bp paired-end reads.
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RNA sequencing data analysis. The unique RNA sequencing reads of six neu-
roblastoma cell lines [SK-N-AS, SY5Y, CHP134, SK-N-DZ, Kelly, and BE(2)-C]
were each aligned to Hg19 using STAR aligner43. The aligned reads were counted
towards Gencode V.18 (ref. 44) to quantify gene expression for all genes using the
union model. Genes were considered expressed if they had an expression of ≥1
counts per million in at least two samples. The expression of all samples were
normalized using the Trimmed Mean of M values model, and differential
expression analysis was performed using EdgeR45, comparing theMYCN-amplified
[CHP134, SK-N-DZ, Kelly, and BE(2)-C] versus the MYCN-non-amplified (SK-N-
AS, SY5Y) cell lines. Genes with an absolute log2 fold change of >1 and a false
discovery rate of <0.05 were considered differentially expressed.
GTEx RNA sequencing data analysis. The publicly available Genotype-Tissue
Expression (GTEx) Release V7 dataset (dbGaP Accession phs000424.v7.p2) pro-
vides expression data of all transcripts from RNA sequencing of 53 normal tissue
sites across nearly 1000 people. lncNB1 transcript expression levels in the normal
tissues were directly obtained through GTEx Portal website [https://gtexportal.org/
home/gene/RP1-40E16.9%20].
TCGA RNA sequencing data analysis. RNA sequencing data from TCGA was
complemented with RNA sequencing data from 493 primary neuroblastoma
tumors26 and processed using Kallisto [https://pachterlab.github.io/kallisto/],
applying a gene index based on Ensembl version 75, to quantify expression of
lncNB1. The RNA sequencing data from TCGA were obtained from various
cancers, including adrenocortical carcinoma (ACC), urothelial bladder cancer,
breast cancer, cervical cancer, cholangiocarcinoma, colon and rectal adenocarci-
noma, diffuse large B-cell lymphoma, esophageal cancer, glioblastoma multiforme,
head and neck squamous cell carcinoma, chromophobe renal cell carcinoma, clear
cell kidney carcinoma, papillary kidney carcinoma, low-grade glioma, liver hepa-
tocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma,
mesothelioma, neuroblastoma, ovarian serous cystadenocarcinoma, pancreatic
ductal adenocarcinoma, pheochromocytoma & paraganglioma, prostate adeno-
carcinoma, colon and rectal adenocarcinoma, sarcoma, cutaneous melanoma,
testicular germ cell cancer, papillary thyroid carcinoma, thymoma, uterine corpus
endometrial carcinoma, uterine carcinosarcoma, uveal melanoma.
ChIP assays. For analyzing histone H3K4 trimethylation at the DEPDC1B and
E2F1 gene promoters and for analyzing E2F1 protein binding at the DEPDC1B
gene promoter, ChIP assays were performed with 5 ug of a rabbit anti-H3K4me3
(ab8580; Abcam), rabbit anti-E2F1 (3742S; Cell Signalling), or control rabbit
antibody, followed by real-time PCR with primers targeting a remote negative
control region or the core promoter region of the DEPDC1B or E2F1 gene46. The
sequences of primers used were: 5′-AGAAGTCTGGGAAGGGTGCT-3′ (forward)
and 5′-ATGCCAGCTTCTTGAGCATT-3′ (reverse) for the negative control region
of the DEPDC1B gene; 5′-GTTTCGGTCGCTGGATAACA-3′ (forward) and 5′-
CTAGGCAGGTGCGACTAAGG-3′ (reverse) for the DEPDC1B gene promoter;
5′-GCAGATGAGGCAAGCAAAGC-3′ (forward) and 5′-CCATCCAAAAGGCA
GTCTAACAT-3′ (reverse) for the negative control region of the E2F1 gene; 5′-
AATGTCATGGGTGAGGCAAGTT-3′ (forward) and 5′-CAACCTGTAGCCCC
CAACAG-3′ (reverse) for the E2F1 gene promoter. Fold enrichment of the
DEPDC1B and E2F1 gene promoter regions was calculated by dividing PCR pro-
ducts from samples immunoprecipitated by the experimental antibodies by PCR
products from samples immunoprecipitated by the control antibody.
Luciferase assays. Modulation of DEPDC1B gene promoter activity by lncNB1
was analyzed by luciferase assays. pGL3 construct carrying DEPDC1B gene pro-
moter (1146 bp) was obtained by directional cloning using primers as listed in
Supplementary Table 6. Deletion mutants of pGL3_DEPDC1B gene promoter were
obtained by whole-around PCR technology using primers as listed in Supple-
mentary Table 6. Luciferase reporter activity was measured using the Dual Luci-
ferase Assay System (Promega). Relative percentage luciferase activity of the
doxycycline treatment condition was normalized by the luciferase activity of the
same reporter construct under vehicle control treatment condition.
Puromycin incorporation assays. Neuroblastoma BE(2)-C and Kelly cells were
transfected with control siRNA, lncNB1 siRNA-1, lncNB1 siRNA-2, RPL35 siRNA-
1, or RPL35 siRNA-2 for 48 h, followed by treatment with vehicle control or with
puromycin (10 µg/ml) for 15 min. For Kelly cells only, the medium was removed
and replaced with fresh growth medium to chase for a further 1 h. Protein was then
extracted for immunoblot analysis with mouse anti-puromycin (1:8000)
(MABE343; Merck Millipore, Burlington, MA) and actin (1:10,000) (A5441;
Sigma) antibodies, or co-immunoprecipitation with 5 µg of mouse control IgG2a
(401501), K isotype (Biolegend San Diego, CA) or 5 µg of mouse anti-puromycin
antibody (MABE343; Merck Millipore) with 700 µg of protein lysate and immu-
noblot analysis with anti-E2F1 (1:500) (3742S; Cell Signalling) and rat anti-
puromycin (1:6000) (MABE341; Merck Millipore) antibodies.
Polysome profiling. BE(2)-C cells were transfected with control siRNA,
lncNB1 siRNA-1, or lncNB1 siRNA-2 for 48 h, followed by treatment with
50 µg/ml of cycloheximide for 5 min. Cells were harvested by trypsinization, and
cell pellets were washed with phosphate-buffered saline and then hypotonic solu-
tion (5 mM Tris pH 7.5, 1.5 mM potassium chloride, and 2.5 mM magnesium
chloride) and lysed in hypotonic lysis buffer (5 mM Tris pH 7.5, 1.5 mM potassium
chloride, 2.5 mM magnesium chloride, 0.5% (v/v) triton X-100, 0.5% (w/v) sodium
deoxycholate, 30 mM dithiothreitol, 50 µg/ml cycloheximide, 1× ethylenediami-
netetraacetic acid free protease inhibitor and 60 U/ml RNasin). Two hundred
microliters of cell lysates containing 40 million cells/sample were loaded into
ultracentrifuge tubes containing 10–40% sucrose gradient prepared with a Bio-
Comp gradient maker and centrifuged in an ultracentrifuge with a SW41 rotor at
36,000 revolutions per minute. Polysomes were fractionated using Teledyne ISCO
Foxy 21 Fractionation System (Teledyne ISCO, Lincoln, NE). Fractions were col-
lected in equal volumes of Qiagen RNA lysis buffer followed by RNA extraction
using the Qiagen RNeasy Kit, RT-PCR, and Affymetrix microarray analysis of RNA
expression.
Fluorescence in situ hybridization and immunocytochemistry. For double
labeling of lncNB1 RNA and RPL35 protein by fluorescence in situ hybridization
and immunocytochemistry, BE(2)-C cells were seeded into cell culture media in
eight-well Lab-tek chamber slides (Thermo Fisher Scientific). After fixation in 4%
paraformaldehyde at room temperature for 30 min, the cells were treated with 3%
hydrogen peroxide for 10 min at room temperature and washed in distilled water
twice and PBS once. FISH was performed through probe hybridization and
amplification with the RNAscope Multiple Fluorescent Reagent Kit v2 Assay
(catalog number 323100-USM; Advanced Cell Diagnostics, Newark, CA). The cells
were hybridized with DapB negative control or custom-made lncNB1 RNA probes
(catalog numbers 310043 and 577481, respectively; Advanced Cell Diagnostics) for
2 h at 40 °C, followed by three amplification steps. The probes were developed by
incubating the cells with RNAscope Multiplex FL v2 HRP-C1 for 15 min at 40 °C,
and OpalTM 690 (PerkinElmer, Waltham, MA) diluted in 1× Plus Amplification
Diluent (1:150) (PerkinElmer) for 30 min at 40 °C and washed with 1× wash buffer
for 2 min at room temperature. The cells were then incubated with RNAscope®
Multiplex FL v2 HRP blocker for 15 min at 40 °C and washed.
After the FISH experiment, the cells were blocked with 10% fetal calf serum and
1% bovine serum albumin for 30 min at room temperature, followed by incubation
with a control IgG or rabbit anti-RPL35 primary antibody (ab209087; Abcam,
Cambridge, UK) (1:30) in 10% fetal calf serum for 1.5 h at room temperature. After
washing, the cells were incubated with a donkey anti-rabbit antibody
(GEHENA934-1ML; GE Healthcare, Chicago, IL) diluted (1:1000) in 10% fetal calf
serum for 1.5 h. The cells were then washed and incubated with OpalTM 520
(PerkinElmer) diluted in 1× Plus Amplification Diluent (1:150) for 10 min at room
temperature. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole
(DAPI) and the slides were mounted with Vectashield antifade mounting medium
(Vector Laboratories, Peterborough, UK). Cell images were captured under a
confocal fluorescence microscope (Leica TCS SP8, Wetzlar, Germany).
Alamar blue assays. Alamar blue assays were performed with our established
protocol39. Briefly, cells were transfected with various siRNAs or treated with
vehicle control or doxycycline in 96-well plates. After 96 h, the cells were incubated
with Alamar blue (Invitrogen) for the last 5 h, and the plates were read on a
microplate reader at 570/595 nm. Results were calculated according to the optical
density absorbance units and expressed as percentage changes in the number of
viable cells, relative to control siRNA-transfected or vehicle control-treated
samples.
BrdU incorporation assays. Neuroblastoma cells were transfected with control
siRNA, lncNB1 siRNA-1 or lncNB1 siRNA-2, or treated with vehicle control or
doxycycline in 96-well plates for 96 h. The cells were then incubated with 5-bromo-
2′-deoxyuridine (BrdU) (Roche) for the final 2 h, fixed, and incubated with
peroxidase-conjugated anti-BrdU antibody. After washing, the peroxidase substrate
containing tetramethyl-benzidine (TMB) (Roche) was added, and the plates were
read on a microplate reader at 405 nm test wavelength and 415 nm reference
wavelength. Results were calculated according to the optical density absorbance
units and expressed as percentage changes in BrdU incorporation, relative to
control siRNA-transfected or vehicle control-treated samples.
Cell cycle analysis. Neuroblastoma cells were transfected with control siRNA,
lncNB1 siRNA-1 or lncNB1 siRNA-2, or treated with vehicle control or doxycy-
cline for 96 h. Cells were then harvested, fixed, and resuspended at a concentration
of 2 × 106 cells per ml in solution containing 2 μg per ml RNase (Sigma) and 50 μg
per ml propidium iodide (Sigma). The cells were examined by flow cytometry using
FACS Calibur machine and FACS Diva software (BD Biosciences). The percentage
of cells at each phase of the cell cycle was analyzed using FlowJo Version 10
(TreeStar Inc., Ashland, OR)39.
Apoptosis analysis. Neuroblastoma cells were transfected with control siRNA,
lncNB1 siRNA-1 or lncNB1 siRNA-2, or treated with vehicle control or
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doxycycline for 96 h. Cells were then stained with Annexin V-FITC and propidium
iodide, followed by flow cytometry analysis of cells positively stained by Annexin
V-FITC and/or propidium iodide, using FACS Canto Flow Cytometer (BD Bios-
ciences). The percentage of Annexin V and/or propidium iodide positive cells was
analyzed with FlowJo Version 10 (ref. 47).
In vivo mouse experiments. Animal experiments were approved by the Animal
Care and Ethics Committee of University of New South Wales, Australia, and the
animals were cared for in agreement with institutional ethics guidelines. Female
Balb/c nude mice aged 5–6 weeks were anesthetized and injected subcutaneously
with either 2 × 106 doxycycline-inducible lncNB1 shRNA-1 BE(2)-C cells or 8 × 106
doxycycline-inducible lncNB1 shRNA-2 Kelly cells into the right flank. Mice were
monitored for tumor development and tumor volume calculated using (length ×
width × height)/2. Mice were fed with either control food without doxycycline or
food containing doxycycline at 600 mg per kg (Meat Free Rat and Mouse ± 600 mg
doxycycline per kg Finished Diet; Specialty Feeds Pty Ltd, Glen Forrest, WA,
Australia), when tumors reached 0.050 cm3 in volume. Tumor sizes were measure
once every 2 days. Mice were culled when tumors reached 1.0 cm3.
Patient tumor sample analysis. lncNB1, DEPDC1B, E2F1, and RPL35 RNA
expression was extracted from the publicly available RNA sequencing SEQC-RPM-
seqcnb1 dataset consisting of 493 human neuroblastoma samples with detailed
information on MYCN amplification status and clinical outcome [http://r2.amc.nl]26.
Statistical analysis. Experiments for statistical analysis were performed at least
three times. Data were examined with Graphpad Prism 6 program and expressed as
mean ± standard error. Differences were analyzed for significance with two-sided
unpaired t-test for two groups or ANOVA among groups.
Correlation between lncNB1, E2F1, and RPL35 expression with DEPDC1B
expression in human neuroblastoma tissues was examined using Pearson’s
correlation. Overall survival of patients was defined as the time from diagnosis until
death or until last contact if the patient did not die. Survival analyses were
performed using GraphPad Prism 6.0 according to the method of Kaplan and
Meier, and comparisons of survival curves were performed using two-sided log-
rank tests. Probabilities of survival and hazard ratios (HRs) were provided with
95% confidence intervals (CIs). Proportionality was confirmed by visual inspection
of the plots of log(2 log(S(time))) versus log(time), which were found to remain
parallel8. A probability value of 0.05 or less was considered statistically significant.
All statistical tests were two-sided.
Data availability
The RNA sequencing, differential gene expression microarray data, and the differential
gene expression microarray data from polysome profiling have been deposited at the
Gene Expression Omnibus website with series numbers of GSE114053, GSE113998, and
GSE132109 respectively. Gene expression in the publicly available RNA sequencing
SEQC-RPM-seqcnb1 dataset consisting of 493 human neuroblastoma samples were
downloaded from the R2 platform [http://r2.amc.nl]. All other relevant data are available
from the corresponding authors on request. The source data underlying Figs. 1c-f, 2b-e,
3a-e, 4a-e, 5a-g, 6a-g, 7a-d, 8a-l and Supplementary Figs 1b, c, 2a-c, 3a-f, 4a-e, 5b, c, 6a-d,
8 and 9a-e, uncropped and unprocessed immunoblot scans are provided as a Source Data
file. Gene expression in 493 human neuroblastoma samples and relevant patient
prognosis information in the Tumor Neuroblastoma SEQC-RPM-seqcnb1 dataset, as
well as gene expression in 88 human neuroblastoma samples and relevant patient
prognosis information in the Tumor Neuroblastoma public-Versteeg dataset, were
downloaded from the R2 platform [http://r2.amc.nl].
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